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Aim: To audit the oncological results and 
perioperative surgical outcome of nephrectomies 
performed in Malta since year 2000. 
Method: A retrospective index case list of all 
nephrectomies carried out by three urological surgeons 
at St Luke’s and Mater Dei Hospitals from 1st September 
2000 to 31st March 2012 was compiled from 
departmental data.  Clinical, radiological and 
histological data were compiled from the case notes and 
hospital intranet computerised investigation results.  
Clinical staging of all patients was revised using the 
Union Internationale Contre le Cancer TNM staging 
2009. All the patients who underwent nephrectomy for 
clear cell renal cell carcinoma were stratified according 
to individual predicted prognosis based on the SSIGN 
score developed by the Mayo clinic. 
Results:  Between September 2000 and March 
2012, 319 nephrectomies were carried out at the Urology 
Unit, of these 288 were carried out for malignancy, 218 
of which were clear cell renal cell carcinoma (RCC). 
112 complications were recorded for the whole cohort; 
two patients died from perioperative complications.  80 
patients passed away, 51 of these as a direct 
consequence of their renal cell cancer.  Median duration 
of follow up was 42.7 months. A Cox model reveals that 
a SSIGN score greater than 6 significantly worsens 
survival rate for RCC (p<<0.001).  
Conclusion: Morbidity following surgery, mortality 
rates, and oncological results in our single centre study 
are acceptable when compared to larger series. 
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Introduction 
Despite the progress made in recent decades with 
the elucidation of various molecular pathways involved 
in the carcinogenesis of renal cell carcinoma of the 
kidney1- 4  which has paved the way for the development 
and introduction of systemic targeted therapies, the 
treatment of renal cell cancer remains predominantly 
surgical, with a paucity of alternative or adjunctive 
oncological options available to patients suffering from 
this aggressive disease.   
The indication for surgical treatment has also 
widened with the consolidation of cytoreductive 
nephrectomy in metastatic disease5-6 and establishment 
of laparoscopic techniques outside of centres of 
excellence.7-8 
Nephrectomy is also sometimes indicated in severe 
benign diseases of the kidney making it a commonly 
performed operation in most urological units worldwide. 
Cancer of the kidney and ureter was seventh most 
commonly diagnosed cancer in Maltese males in 2012 
with an age standardised incidence of 15.0/100,000 9 and 
represents a significant proportion of the patients seen at 
our institution’s Urology Unit.   
The increasing use of cross sectional imaging for 
investigation of various medical complaints has also 
resulted in an increasing incidence of incidental 
asymptomatic renal tumours, a phenomenon common to 
most urology units in the developed world. 10 
 
Method 
A retrospective index case list of all nephrectomies 
carried out by three urological surgeons at St Luke’s and 
Mater Dei Hospitals from 1st September 2000 to 31st 
March 2012 was compiled from departmental data.  
Operative data relating to procedures carried out within 
our Urology Unit is compiled in a prospective manner 
using a Microsoft Access®-based database, allowing 
accurate and reliable retrieval of the index case list. 
Clinical presentation, prognostic factors, histology, 
radiological characteristics, surgical technique, post-
operative morbidity and mortality, length of hospital 
stay and vital status were compiled from the case notes 
and hospital intranet radiological and clinical databases.  
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Survival data was corroborated with death certificates 
obtained from the Department of Health Information.  
Staging of all patients was revised using the TNM 
staging Union Internationale Contre le Cancer TNM 
staging 2009, which has been externally validated in 
2011.11,12  Information from preoperative CT scans and 
histopathological report of the resected specimen were 
combined to restage all the patients in the cohort.  
All the patients who underwent nephrectomy for 
clear cell renal cell carcinoma were stratified according 
to individual prognosis based on the Stage, Size, Grade, 
Necrosis Score Algorithm (SSIGN) developed by the 
Mayo clinic 13 and recently externally validated in a 
European study. 15  As the SSIGN score is validated for 
use only in clear cell renal cell carcinoma, patients 
whose pathology was not clear cell renal cell carcinoma 
were excluded from survival analysis, although these 
records were included in other analyses. 35 patients who 
developed a second malignancy (excluding squamous 
cell carcinoma or basal cell carcinoma of the skin) 
during the study period were excluded from this 
analysis.   
 
Results 
Patient and tumour characteristics are shown in 
Table 1.  319 patients underwent nephrectomy between 
September 2000 and March 2012.  288 patients 
underwent nephrectomy for tumour, of these tumours 
218 were clear cell renal cell carcinomas.  Other 
indications for nephrectomy included inflammatory or 
infective pathologies (26), benign masses (36), 
polycystic kidney disease (4) and vesico-ureteral reflux 
with dysplastic kidney (1).  75% (n=241) of the patient 
cohort were diabetic, other risk factors for renal 
malignancy included current smoking at time of surgery 
(16.9%, n=54), smoking history (14.4%, n=46) and 
positive family history (1.5%, n=5).   
The local incidence of incidentally detected kidney 
tumours has been rising over the last decade (35%, 
n=115) (Figure 1).  The total number of nephrectomies 
performed per year has also been increasing in parallel 
over the study period. Loin pain was the presenting 
symptom in 24% (n=82), gross haematuria in 23% 
(n=79), pyrexia of unknown origin in 3% (n=11), 
anaemia in 2% (n=8) and abdominal mass in another 2% 
(n=6). 11 patients (3%) presented with uncommon 
symptoms, such as nasal congestion from posterior nasal 
space metastasis, visual deterioration from occipital lobe 
metastasis and skull metastasis.  Information on clinical 
presentation is not available in 26 patients (8%). 
The majority of the patients underwent open radical 
nephrectomy (70%), followed by open partial nephrectomy 
(Table 1). One patient underwent joint procedure with 
cardiothoracic surgeons with radical nephrectomy, inferior 
vena cava exploration and removal of right atrial tumour 
thrombus under cardio-pulmonary bypass. 
Table 1: Patient and Tumour Characteristics 
Total  number of patients 319 
Nephrectomy for tumour 288 
Males (%) 191 (60) 
Females (%) 128 (40) 
Age (years) mean (range) ± 
SD 58.7 (22 - 90) 11.85 
Radiological Size (cm) mean 
(range) 6.3 (1 -20) 
Tumour location   
Upper pole 92 
Central 90 
Lower pole 77 
Complete renal infiltration 10 
Renal pelvis 11 
Ureter 4 
Not available 4 
TNM Distribution   
Localised at presentation   
T1a N0 M0 71 
T1b N0 M0 51 
T2a N0 M0 15 
T2b N0 M0 19 
T3a N0 M0 29 
T3b N0 M0 7 
T3c N0 M0 2 
T4 N0 M0 0 
Metastatic at presentation   
T2a N1 M0 1 
T3a N1 M0 1 
T3b N1 M0 1 
T4 N1 M0 1 
T1b N0 M1 1 
T2b N0 M1 4 
T3a N0 M1 4 
T3b N0 M1 1 
T3a N1 M1 1 
T3b N1 M1 1 
T3c N1 M1 2 
T4 N1 M1 1 
Surgical Procedure   
Open Radical Nephrectomy 225 
Open Partial Nephrectomy 34 
Nephroureterectomy 15 
Simple Nephrectomy 15 
Laparoscopic Partial 13 
No Data 11 
Laparoscopic Radical 5 
Open Radical and 
Sternotomy  1 
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Figure 1: Incidence of incidental tumours and total 
















Morbidity and mortality data are shown in Table 2.  
A total of 62 patients (20%) suffered from a post-
operative complication.  46 patients suffered one 
complication, 12 patients suffered two events and four 
patients suffered three complications.   
After excluding post-operative transfusion (9.7%), 
important complications included pneumonia (15 
patients), deterioration in renal function requiring 
temporary dialysis (8 patients), wound complications (16 
patients) and intestinal obstruction requiring laparotomy 
(3 patients).  Two patients were rendered anephric by 
surgery in the context of adult polycystic kidney disease, 
and the need for permanent dialysis was determined by 
pre-existing end-stage renal failure.   
Two patients died within 30 days of surgery from 
complications related to the nephrectomy, one patient 
sustained a myocardial infarct followed by cardiac arrest 
and a second patient developed DIC after severe 
haemorrhage and multiple blood transfusions. 
Oncological results are shown in Table 3.  288 
patients who had histologically proven renal cancer were 
included for analysis of oncological outcome.  Patients 
whose final histological diagnosis was clear cell renal 
cancer (n=218) were stratified and analysed according to 
the SSIGN score.  This scoring system is based on the 
pathological tumour stage, tumour size, tumour necrosis, 
nodal status and presence of distant metastasis.  Every 
patient with known clear cell renal cell carcinoma was 
included in one of five risk groups.  Crude survival and 
cancer specific survival for each group was calculated 
and showed using the Kaplan Meier method. (Figures 2 
and 3).    
The same cohort of patients was then divided into 
two risk groups using a cut off of SSIGN score 6, with 
the group having a score of > 6 having a statistically 
significant survival disadvantage (p<0.001). (Figures 4 




Table 2: Summary of Complications 
Haematological   Renal/urological   









Renal dysfunction - no 
dialysis 1 
    UTI 1 
Respiratory   Clot colic with obstruction 1 
Pneumonia 15 
Calculous obstruction 
single kidney 1 
Intraoperative 
desaturation 1 Urocutaneous fistula 1 
Pleural effusion 1     
Cardiovascular   Drug related   
MI/cardiac arrest 1 Opiate overdose 3 
Arrhythmia 
(cardioversion) 1 Drug rash 1 
Arrhythmia 
(pharmacological rx) 2 
Hand and Foot Syndrome 
(TKIs) 1 
Angina 2     
Cerebrovascular 
event 1     
GIT/Intrabdominal   Body Wall   
Bowel obstruction 
(conservative) 3 Wound infection 7 
Bowel obstruction 
(laparotomy) 3 Incisional hernia 7 
GI bleed 2 Wound haematoma 2 
Psoas abscess 
(surgical drainage) 1     
Systemic   Perioperative death   
Sepsis 3 DIC 1 
Hyperglycaemia 2 MI 1 
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Table 3: Follow up data 
Follow up (days) mean (range) 1282 (13 - 4246) 
Adjuvant Oncological Treatment   
Systemic chemotherapy 8 
External beam radiotherapy 15 
Interferon 2 
Tyrosine kinase inhibitor 7 
Local Recurrence n (%) 10 (3.4) 
Distant Metastasis n (%) 43 (14.9) 
Metastasis free survival (metastatic pts 
only) (days) mean (range) 566 (8 - 3186) 
Local recurrence free survival (recurring 
pts only) (days) mean (range) 280 (103 - 645) 
Metastasis sites n of pts, (%)   
Lung 21 (30) 
Bone 12 (17) 
Liver 9 (13) 
Retroperitoneal LNs 7 (10) 
Adrenal 6 (8) 
Brain 3 (4) 
Pancreas 2 (3) 
Other  11 (15) 
Second Primary Tumours n of pts, (%) 35, (12%) 
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Figure 5: 10 year cancer specific survival stratified per 





















In this series, nephrectomy resulted in acceptable 
morbidity rates.  The post-operative 30 day surgical 
mortality rate of 0.62 % compares well with published 
figures ranging from 0.77 to 2.3%. 16 Post-operative 
complication rates are also in line with other published 
series with a total morbidity rate of 20% (with studies 
quoting complication rates between 2 and 35%). 17, 18 
Oncological results in the clear cell carcinoma 
group also compare favourably with larger series 
published by tertiary high volume centres (Table 4).  
Our results in the very poor prognosis group are 
significantly worse, however these patients were mostly 
(19 out of 20) patients who presented with metastatic 
disease and had cytoreductive or palliative nephrectomy 
to alleviate symptoms.  These metastatic patients were 
not included in the series by Frank et al 13 or Zigeuner et 
al 14 and this may explain the differences in outcomes 
observed. In our series the SSIGN score was confirmed 
to be a good indicator of predicted survival in clear cell 
carcinoma patients undergoing radical or partial 
nephrectomy. 
 
Table 4: 10 year Cancer Specific Survival stratified by 
SSIGN score groups 
 
This series also outlines local trends in kidney 
cancer surgery, with partial nephrectomy slowly taking 
over radical nephrectomy as the technique of choice, 19, 
20 in accordance with European Association of Urology 
guidelines.21 Partial nephrectomy, although being a 
complex and challenging procedure, affords preservation 
of renal function which translates lower long term 
cardiovascular mortality and better overall survival, 
compared to radical nephrectomy.22-24 The introduction 
of laparoscopic techniques into local practice over the 
last few years is also translating in lower patient 
morbidity. 
Our study has some limitations and numerous 
strong points.  Being the only urology unit in the 
country, follow up is mostly complete with no patients 
lost to follow up because of migration.  Duration of 
follow ups is adequate with 10 year survival being 
presented rather than the traditional 5 year survival rates. 
Patients readmitted with post-operative complications 
are cared for by the same unit, so recording morbidity is 
an easier task.  Mortality data was corroborated by death 
certification data obtained from the National Cancer 
Registry to minimise inaccuracy. 
Limitations include those inherent to a retrospective 
audit, including incomplete data, reliance on potentially 
inaccurate medical notes and bias. Recorded 
complications were not graded according to a validated 
severity score because of scant clinical details which 
precluded accurate stratification.  The performance 
status, co-morbidity and ASA score were not recorded, 
factors which would be expected to influence post-
operative complications rates.   
SSIGN 
Score       









(n = 201) 
(Mayo 
Clinic) 
Frank I et 
al  – 10 yr 
survival 
(n = 1801) 
 Zigeuner et 
al   - 10 yr 
survival (n = 
2333) 
0 - 2 85 95% 97% 93% 
3 - 4 33 96% 78% 72% 
5 - 6 35 56% 57% 46% 
7 - 9  28 23% 30% 22% 
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Data regarding BMI and blood pressure were not 
recorded, both obesity and hypertension now being 
considered as risk factors for kidney cancer 
carcinogenesis.  The issue of obesity and metabolic 
syndrome could have significant local importance, as 
shown by the high incidence of diabetics in our cohort. 
Lastly, cancer specific survival rather than overall 
survival was considered as the hard oncological end 
point, whilst overall survival might represent 




Surgical morbidity and mortality rates and 
oncological results in our single centre study compare 
well to larger series.  Over the study period changes in 
international guidelines and progress in surgical 
techniques have been adapted to our local practice with 
good effect.  
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